AureoGen Funding:

AureoGen has to date raised approximately $6 million from the following sources:

• $200,000. Start up funding from the Michigan Economic Development Corporation (MEDC), September 4th 2003.
• $1,994,476. A convertible loan from the Michigan Tri-Technology Corridor (MTTC), for development of genetic tools and methodologies for efficient engineering of cyclic peptide producing organisms, June 29th, 2004.
• $162,982. Phase I SBIR grant from the National Institutes of Health (NIH), for a project entitled Novel Antifungals by Engineering a NRPS gene, September 17th, 2004.
• $1,450,508. Three year grant from the National Institutes of Standards and Technology, Advanced Technology Program (NIST/ATP), for a project entitled “A Genetic Engineering Technology Platform for Production of Novel Cyclic Peptide-Based Drugs, September 28th, 2004.
• $225,000. Investment/convertible loan from the Western Michigan University (WMU) Bioscience Research and Commercialization Center (BRCC), April 1, 2005.
• $1,978,701. Three year SBIR grant from the National Institutes of Health (NIH), for Phase II of the project Novel Antifungals by Engineering a NRPS gene, May 15th, 2006.

The company is actively pursuing additional funding from both public and private sources.